Soligenix, Inc. (SNGX)
| Previous close | 4.9600 |
| Open | 4.2000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 4.0100 - 4.8050 |
| 52-week range | 0.3000 - 4.8050 |
| Volume | |
| Avg. volume | 2,731,739 |
| Market cap | 4.009M |
| Beta (5Y monthly) | 1.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting Soligenix Inc’s (Nasdaq: SNGX) key achievements and pathway to regulatory success through its lead product candidate, HyBryte™ (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma, a rare and chronic cancer. Soligenix is targeting a CTCL therapeutics market that reached a value of $520 million in 2023. The company
- PR Newswire
Soligenix Announces Reverse Stock Split
Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares. The reverse stock split will become effective at 4:00 p.m. on Wednesday, June 5, 2024. Soligenix's common stock will continue to be traded on
- PR Newswire
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, encourages its eligible stockholders to vote their shares at the upcoming reconvened meeting on May 30, 2024. The Company and its Board of Directors believe it is important for all stockholders to make their voices heard. The Company urges all stockholders to exercise their right to vote t
